Post job

Med Immune Inc main competitors are Gilead Sciences, Vertex Pharmaceuticals, and Merck.

Competitor Summary. See how Med Immune Inc compares to its main competitors:

  • Johnson & Johnson has the most employees (134,500).
  • Employees at Gilead Sciences earn more than most of the competitors, with an average yearly salary of $99,828.
Work at Med Immune Inc?
Share your experience

Med Immune Inc vs competitors

CompanyFounding dateZippia scoreHeadquarters# of LocationsRevenueEmployees
1988
4.2
Gaithersburg, MD1$1.7B5,000
1989
4.6
Boston, MA5$11.0B3,400
1891
4.6
Kenilworth, NJ31$64.2B74,000
1886
4.7
New Brunswick, NJ26$88.8B134,500
1987
4.5
San Diego, CA4$241.5M116
1997
4.7
Bothell, WA3$2.0B900
1987
4.5
Foster City, CA9$28.8B11,800
1987
4.8
Gaithersburg, MD3$682.2M791
Nanotherapeutics, Inc.
-
3.5
Alachua, FL1--
1954
4.9
Greenfield, IN2$4.4B10,200
LSNE Contract Manufacturing
1997
3.7
Manchester, NH1$9.2M15

Rate how well Med Immune Inc differentiates itself from its competitors.

Zippia waving zebra

Med Immune Inc salaries vs competitors

Among Med Immune Inc competitors, employees at Gilead Sciences earn the most with an average yearly salary of $99,828.

Compare Med Immune Inc salaries vs competitors

CompanyAverage salaryHourly salarySalary score
Med Immune Inc
$56,355$27.09-
Vertex Pharmaceuticals
$95,952$46.13-
Merck
$90,328$43.43-
Johnson & Johnson
$76,686$36.87-
Ligand Pharmaceuticals
$82,001$39.42-
Seagen
$85,008$40.87-

Compare Med Immune Inc job title salaries vs competitors

CompanyHighest salaryHourly salary
Med Immune Inc
$84,269$40.51
Elanco
$96,012$46.16
Ligand Pharmaceuticals
$91,776$44.12
Vertex Pharmaceuticals
$84,516$40.63
Merck
$83,859$40.32
Novavax
$81,492$39.18
Gilead Sciences
$79,533$38.24
Nanotherapeutics, Inc.
$71,894$34.56
Seagen
$70,226$33.76
Johnson & Johnson
$68,306$32.84
LSNE Contract Manufacturing
$66,282$31.87

Do you work at Med Immune Inc?

Does Med Immune Inc effectively differentiate itself from competitors?

Med Immune Inc jobs

Med Immune Inc demographics vs competitors

Compare gender at Med Immune Inc vs competitors

Job titleMaleFemale
Merck54%46%
Novavax55%45%
Vertex Pharmaceuticals56%44%
Gilead Sciences56%44%
Med Immune Inc58%42%
Johnson & Johnson58%42%

Compare race at Med Immune Inc vs competitors

CompanyWhiteHispanic or LatinoBlack or African AmericanAsianUnknownDiversity score
51%8%16%21%4%
7.3
44%20%8%23%6%
9.8
54%16%10%15%4%
9.8
56%16%10%14%4%
9.8
45%13%18%17%7%
8.8
56%14%7%17%6%
9.7

Med Immune Inc and similar companies CEOs

CEOBio
Daniel O’Day
Gilead Sciences

Joaquin Duato
Johnson & Johnson

John L. Higgins
Ligand Pharmaceuticals

John L. Higgins has over 14 years of corporate development, financing, strategic planning, commercialization, and investment banking experience in the biopharmaceutical industry. He is the chief executive officer of [Ligand Pharmaceuticals](https://www.crunchbase.com/organization/ligand-pharmaceuticals#/entity), a biotechnology company that focuses on the discovery and early-stage development of pharmaceuticals for medical needs in the United States. Prior to joining Ligand, Higgins was the chief financial officer; and executive vice president of finance, administration, and corporate development at Connetics Corporation, a public specialty pharmaceutical company, until its acquisition by Stiefel Laboratories, Inc. in 2006. During his service period of nearly 10 years at Connetics, he played a key leadership role in numerous strategic initiatives, including major acquisitions, divestitures, multiple product and technology licensing transactions, and financings. Prior to joining Connetics, Higgins was the executive vice president of corporate development at BioCryst Pharmaceuticals, Inc. and was a member of the health care investment banking team at Dillon, Read & Company, Inc. He has served numerous public and private corporate boards and currently is a director at BioCryst Pharmaceuticals, Inc. where he serves as chairman of the audit committee. Higgins earned a bachelor’s degree in Economics from Colgate University.

Robert M. Davis
Merck

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

Richard Maradie
Novavax

Richard Maradie is a Chief Executive Officer at NOVAVAX INC and is based in Rockville, Maryland.

Roger D. Dansey
Seagen

Reshma Kewalramani M.d
Vertex Pharmaceuticals

Reshma Kewalramani (born 1973), is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. She is the first female CEO of a large US biotech company. She was previously the chief medical officer and vice president of global medicines development and medical affairs at Vertex.

Jeffrey N. Simmons
Elanco

Med Immune Inc competitors FAQs

Search for jobs